Abstract

Pulmonary hypertension is treated with drugs that stimulate cGMP or cAMP signalling. Both nucleotides can activate Kv7 channels, leading to smooth muscle hyperpolarisation, reduced Ca2+ influx and relaxation. Kv7 activation by cGMP contributes to the pulmonary vasodilator action of nitric oxide, but its contribution when dilation is evoked by the atrial natriuretic peptide (ANP) sensitive guanylate cyclase, or cAMP, is unknown. Small vessel myography was used to investigate the ability of Kv7 channel blockers to interfere with pulmonary artery relaxation when cyclic nucleotide pathways were stimulated in different ways. The pan-Kv7 blockers, linopirdine and XE991, caused substantial inhibition of relaxation evoked by NO donors and ANP, as well as endothelium-dependent dilators, the guanylate cyclase stimulator, riociguat, and the phosphodiesterase-5 inhibitor, sildenafil. Maximum relaxation was reduced without a change in sensitivity. The blockers had relatively little effect on cAMP-mediated relaxation evoked by forskolin, isoprenaline or treprostinil. The Kv7.1-selective blocker, HMR1556, had no effect on cGMP or cAMP-dependent relaxation. Western blot analysis demonstrated the presence of Kv7.1 and Kv7.4 proteins, while selective activators of Kv7.1 and Kv7.4 homomeric channels, but not Kv7.5, caused pulmonary artery relaxation. It is concluded that Kv7.4 channels contribute to endothelium-dependent dilation and the effects of drugs that act by stimulating cGMP, but not cAMP, signalling.

Highlights

  • Drugs that stimulate cyclic nucleotide signalling in pulmonary artery smooth muscle cells (PASMCs) are the mainstay of targeted therapies used to treat pulmonary arterial hypertension (PAH)

  • The results show that Kv7 channel activation contributes substantially to cyclic guanosine monophosphate (cGMP)-dependent dilation of pulmonary artery evoked by the nitric oxide (NO) or atrial natriuretic peptide (ANP) pathways, but not cyclic adenosine monophosphate (cAMP)-mediated dilation

  • The results of this study strongly support a role for Kv7 channels, but not BKCa channels, in mediating cGMP-dependent pulmonary vasodilation

Read more

Summary

Introduction

Drugs that stimulate cyclic nucleotide signalling in pulmonary artery smooth muscle cells (PASMCs) are the mainstay of targeted therapies used to treat pulmonary arterial hypertension (PAH) They mimic the actions of the endothelium-derived mediators, nitric oxide (NO) and prostacyclin (PGI2 ), which are depleted in pulmonary hypertension due to loss of endothelial function (e.g., [1,2]). PGI2 acts on Gs -protein-coupled receptors on the smooth muscle cell membrane to stimulate adenylate cyclase (AC) and cyclic adenosine monophosphate (cAMP) signalling. These pathways in PASMCs are widely documented (e.g., [4,5]), the precise mechanisms of cyclic nucleotide action remain unresolved

Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call